Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • threads
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Safety
    • Nurse Well-Being
    • Drug Reference Sheets
    • ONS Congress
    • Specific Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Get Involved
    Stories View All
    View All
    cozy hospital room with bed and computer
    Interprofessional Issues
    Novel, Interprofessional Approach Enhances Bed Assignments for Individuals on Antineoplastic Drugs in a Hospital Setting
    August 22, 2024
    hand touching futuristic screen that represents artificial intelligence
    Nurse Empowerment
    How AI Can Support Oncology Nurses’ Spirit of Inquiry
    August 15, 2024
    person with brown clothes holding patient's hand in support on hospital bed
    Nurse Empowerment
    Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession
    July 04, 2024
    publish with ONS Voice
    Nursing Professional Development
    Publish Your First Article With ONS Voice
    March 19, 2024
    A family of nurses
    Nurse Well-Being
    When Health Care Is Woven in Our Family Fabric, We Find Support in Unexpected Places
    March 07, 2024
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    IV drip
    Drug Reference Sheets

    Oncology Drug Reference Sheet: Tarlatamab-Dlle

    Tarlatamab-dlle (Imdelltra™) was granted accelerated approval in May 2024 for the treatment of extensive-stage small cell lung cancer with progression on or after a platinum chemotherapy regimen.

    August 27, 2024
    Gloved hand pressing a cross button next to a checklist
    Standards

    Are You Following the Latest Chemo Safety Recommendations?

    In response to the ever-changing practice of cancer care, in May 2024, the American Society of Clinical Oncology (ASCO) and ONS released updates to their administration safety standards to provide clarification and guidance for oncology healthcare professionals. Here’s what you need to know about the changes as an oncology nurse.

    July 16, 2024
    Oncology Drug Reference Sheet: Margetuximab-Cmkb
    Drug Reference Sheets

    Oncology Drug Reference Sheet: Margetuximab-Cmkb

    Margetuximab-cmkb (Margenza®) received U.S. Food and Drug Administration approval in December 2020 for previously treated adults with metastatic HER2-positive breast cancer after clinical trials demonstrated increased progression-free and overall survival. 

    December 26, 2023
    Oncology Drug Reference Sheet: Selinexor
    Drug Reference Sheets

    Oncology Drug Reference Sheet: Selinexor

    After clinical trials demonstrated a 25% response rate in patients with multiple myeloma, selinexor (Xpovio®) received initial, accelerated U.S. Food and Drug Administration approval in 2019.

    September 27, 2022
    Oncology Drug Reference Sheet: Avapritinib
    Drug Reference Sheets

    Oncology Drug Reference Sheet: Avapritinib

    First approved by the U.S. Food and Drug Administration in 2020 for treatment of gastrointestinal stromal tumors (GIST), avapritinib’s (AyvakitTM) approval was extended in 2021 for treatment of advanced systemic mastocytosis (AdvSM). Both approvals are for patients with PDGFR-alpha genetic variants.

    April 26, 2022
    Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy
    Drug Reference Sheets

    Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy

    Initially marketed in April 2020 for treatment of adults with metastatic triple negative breast cancer, sacituzumab govitecan-hziy (Trodelvy®) received an additional approval in 2021 for the treatment of patients with locally advanced or metastatic urothelial cancer with prior treatments.

    September 28, 2021
    Oncology Drug Reference Sheet: Trilaciclib
    Clinical Practice

    Oncology Drug Reference Sheet: Trilaciclib

    On February 12, 2021, the U.S. Food and Drug Administration approved trilaciclib (CoselaTM), a parenteral inhibitor of cyclin-dependent kinase, to prevent myelosuppression when administered prior to chemotherapy administration. The approval is currently limited to the use of trilaciclib before treatment with platinum- and etoposide-containing regimens and topotecan-containing regimens for treatment of extensive-stage small cell lung cancer.

    May 25, 2021
    Surveys Show PPE Is Still in Short Supply
    Personal Protective Equipment (PPE)

    Surveys Show PPE Is Still in Short Supply

    A perhaps unexpected phenomenon the COVID-19 coronavirus pandemic created around the world was countless supply shortages. Most at worst were inconvenient (e.g., yeast shortages from pandemic breadmaking) or humorous (e.g., toilet paper memes), but one that oncology nurses experienced far too close to home was downright deadly: lack of proper personal protective equipment (PPE) supplies for handling hazardous drugs.  

    April 16, 2021
    Oncology Drug Reference Sheet: Decitabine and Cedazuridine
    Cancer Treatments

    Oncology Drug Reference Sheet: Decitabine and Cedazuridine

    In July 2020, the U.S. Food and Drug Administration approved decitabine and cedazuridine (Inqovi®) tablets for the treatment of adults with myelodysplastic syndromes. 

    March 30, 2021
    Oncology Drug Reference Sheet: Alpelisib
    Clinical Practice

    Oncology Drug Reference Sheet: Alpelisib

    When used in combination with fulvestrant, alpelisib (Piqray®) produced complete or partial responses in 29% of patients with PIK3CA-altered, estrogen receptor-positive advanced breast cancer in clinical trials. The U.S. Food and Drug Administration approved it for use in 2019.

    December 29, 2020
    Oncology Drug Reference Sheet: Zanubrutinib
    Clinical Practice

    Oncology Drug Reference Sheet: Zanubrutinib

    Zanubrutinib (BrukinsaTM) received U.S. Food and Drug Administration accelerated approval on November 14, 2019, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

    September 22, 2020
    A Primer on Urothelial Cancer
    Clinical Practice

    A Primer on Urothelial Cancer

    The urinary system, including the bladder, ureters, urethra, and renal pelvis, is lined with urothelial tissue. Urothelial carcinoma is the predominant histologic type of cancer in that system, and 90% of tumors are located in the bladder. With more than 81,400 new cases and nearly 18,000 deaths estimated for 2020, bladder cancer is the fifth most prevalent type of cancer in the United States.

    September 21, 2020
    Proper PPE Procedures for COVID-19
    COVID-19

    Proper PPE Procedures for COVID-19

    Although many oncology nurses are well versed in donning and doffing (removal) of personal protective equipment (PPE) for administering hazardous drugs, but not infection control. Additionally, nursing colleagues in other specialties may not wear PPE as part of their daily practice. As the COVID-19 novel coronavirus pandemic changes that, oncology nurses should understand PPE use for infection control to promote safety for nurses and patients.   

    March 17, 2020
    Oncology Drug Reference Sheet: Blinatumomab (Blincyto®)

    Oncology Drug Reference Sheet: Blinatumomab

    Blinatumomab received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of B-cell precursor acute lymphoblastic leukemia. The drug’s unique administration procedures have prompted nurses to evaluate their practice for safety.

    November 27, 2019
    Oncology Drug Reference Sheet: Talazoparib (Talzenna®)

    Oncology Drug Reference Sheet: Talazoparib

    Initially approved in 2018, talazoparib (Talzenna®) capsules are indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene HER2-negative locally advanced or metastatic breast cancer.

    May 21, 2019
    What USP Means for Safe Oncology Nursing Practice
    Safety

    What USP Means for Safe Oncology Nursing Practice

    Nurses in oncology who compound hazardous drugs may be familiar with the U.S. Pharmacopeial Convention (USP) because of chapter <795> related to compounding nonsterile medications and chapter <797> addressing compounding sterile medications. But what is USP really, and why does it have an impact on oncology nursing practice?

    May 07, 2019
    Patient Safety

    Respecting Hazardous Drugs Protects Nurses, Patients and Eliminates Fear

    A recent article on the Scrubs website, “Chemotherapy Drugs are Killing Nurses” shared important facts and concerns regarding the handling of hazardous drugs. It also highlighted the need for comprehensive education and collaboration to establish a culture of safety around the use of these drugs by building respect, not fear, for hazardous drugs in the workplace.
    April 18, 2016

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    Kristine B. LeFebvre DNP, RN, NPD-BC, AOCN®

    Kristine B. LeFebvre, DNP, RN, NPD-BC, AOCN®, is an oncology clinical specialist for ONS.
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Contact Us
  • Advertising
  • Newsroom
  • Conferences
  • RSS Feed
  • Sitemap
  • Legal Notices

    • Subscribe to ONS Voice Updates

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • threads
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2024 Oncology Nursing Society
    Back to Top ▲